Reported a net loss of $7,027,410 for the fiscal year ended December 31, 2025, an improvement from $11,507,947 in 2024. Accumulated deficit increased to $110,465,509 as of December 31, 2025. Cash balance significantly decreased to $762,365 as of December 31, 2025, from $3,229,480 in 2024. Auditors have raised substantial doubt about the company's ability to continue as a going concern. Implemented cost reduction measures in 2026, including a reduction in headcount and prioritizing development over clinical activities, impacting the timing of a future FDA De Novo submission for its TAEUS liver application. The Board of Directors initiated a process on March 25, 2026, to evaluate a range of strategic alternatives, including investments, mergers, asset sales, or a sale of the company. Expanded business strategy in 2025 to include a Digital Asset Treasury (DAT) initiative, managed with Arca Investment Management, focusing on decentralized finance (DeFi) assets like HYPE. Purchased $3,000,000 of digital intangible assets (HYPE tokens) in 2025, which had a fair value of $2,009,960 and an unrealized loss of $995,161 as of December 31, 2025. Recognized $5,121 in digital asset staking compensation for the year ended December 31, 2025. Research and development expenses decreased by 42% to $1,849,996 in 2025 from $3,190,293 in 2024. Sales and marketing expenses decreased by 67% to $189,470 in 2025 from $571,040 in 2024. General and administrative expenses decreased by 47% to $3,723,635 in 2025 from $7,055,814 in 2024, primarily due to a $2,525,179 inventory reserve in 2024 that was not present in 2025. The company is not in compliance with Nasdaq's minimum stockholders' equity requirement and expects a delisting determination letter, planning to request a hearing. As of March 31, 2026, there were 1,240,751 shares of common stock outstanding.